CORONA Remedies Limited (CORONA) Q2 FY27 Financial Results: PAT ₹60.1 & Revenue ₹422.4 Cr

CORONA Remedies Limited reported unaudited standalone revenue of [amount not verified] and consolidated net profit of ₹60.10 crores for Q1 FY27, up 21.9% YoY and 30.1% YoY respectively, with earnings per share at [amount not verified]The results include a statutory exceptional item of ₹19.10 crores related to new labour codes, resulting in adjusted profit before tax of ₹240.15 crores. The company highlighted strategic progress including the inauguration of an EU-GMP approved female hormone manufacturing facility in Ahmedabad on 30 June 2026 and integration of the Wokadine brand, maintaining its 5th rank in gynaecology. Forward-looking statements were included with standard risk disclosures.